Novo Nordisk (NVO) Stock Dips Despite Promising Childhood Obesity Trial Results
Key Highlights In the STEP Young study, 40.4% of children between ages 6 and 12 successfully dropped below obesity thresholds following 68 weeks of semaglutide treatment Zero participants rec




